Compare Novartis with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ABBOTT INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ABBOTT INDIA NOVARTIS/
ABBOTT INDIA
 
P/E (TTM) x 760.9 56.5 1,346.5% View Chart
P/BV x 22.9 16.7 136.7% View Chart
Dividend Yield % 1.9 0.4 470.2%  

Financials

 NOVARTIS   ABBOTT INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
ABBOTT INDIA
Mar-19
NOVARTIS/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs9808,834 11.1%   
Low Rs6005,458 11.0%   
Sales per share (Unadj.) Rs198.71,731.1 11.5%  
Earnings per share (Unadj.) Rs21.0211.9 9.9%  
Cash flow per share (Unadj.) Rs22.3219.9 10.1%  
Dividends per share (Unadj.) Rs10.0065.00 15.4%  
Dividend yield (eoy) %1.30.9 139.1%  
Book value per share (Unadj.) Rs307.5945.2 32.5%  
Shares outstanding (eoy) m24.6921.25 116.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.1 96.3%   
Avg P/E ratio x37.733.7 111.7%  
P/CF ratio (eoy) x35.532.5 109.2%  
Price / Book Value ratio x2.67.6 34.0%  
Dividend payout %47.730.7 155.5%   
Avg Mkt Cap Rs m19,508151,848 12.8%   
No. of employees `0000.63.5 16.7%   
Total wages/salary Rs m1,1714,356 26.9%   
Avg. sales/employee Rs Th8,445.410,555.5 80.0%   
Avg. wages/employee Rs Th2,015.71,249.9 161.3%   
Avg. net profit/employee Rs Th891.01,292.2 69.0%   
INCOME DATA
Net Sales Rs m4,90736,786 13.3%  
Other income Rs m7831,133 69.1%   
Total revenues Rs m5,68937,919 15.0%   
Gross profit Rs m1236,047 2.0%  
Depreciation Rs m32169 18.8%   
Interest Rs m1623 70.7%   
Profit before tax Rs m8586,989 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3402,485 13.7%   
Profit after tax Rs m5184,503 11.5%  
Gross profit margin %2.516.4 15.2%  
Effective tax rate %39.635.6 111.5%   
Net profit margin %10.612.2 86.2%  
BALANCE SHEET DATA
Current assets Rs m8,05527,610 29.2%   
Current liabilities Rs m1,8508,569 21.6%   
Net working cap to sales %126.451.8 244.3%  
Current ratio x4.43.2 135.1%  
Inventory Days Days4560 74.8%  
Debtors Days Days3427 123.8%  
Net fixed assets Rs m1501,057 14.2%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m7,46919,873 37.6%   
Net worth Rs m7,59220,086 37.8%   
Long term debt Rs m00-   
Total assets Rs m9,82429,409 33.4%  
Interest coverage x54.9311.6 17.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.3 39.9%   
Return on assets %5.415.4 35.3%  
Return on equity %6.822.4 30.4%  
Return on capital %11.534.9 33.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m58369 15.6%   
Fx outflow Rs m1,3264,918 27.0%   
Net fx Rs m-1,269-4,549 27.9%   
CASH FLOW
From Operations Rs m-1,9434,991 -38.9%  
From Investments Rs m2,742-2,570 -106.7%  
From Financial Activity Rs m-298-1,428 20.9%  
Net Cashflow Rs m501993 50.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 7.9 25.3%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.1 125.7%  
Shareholders   41,647 18,270 228.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 3, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ALKEM LABORATORIES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS